Skip to main content

Aligos Therapeutics, Inc.

ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001799448

No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Q3 2021 vs. Q2 2021

How the institutions holding Aligos Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of ALGS: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders5868+10
Shares27.0M31.2M+4.19M (+15.5%)
Value$550.5M$483.9M−$66.6M (−12.1%)

New holders (16)

Institutions that held Aligos Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to ALGS in Q3 2021
InstitutionSharesValue% of portfolio
Sphera Funds Management Ltd.249,197$3.87M0.38%
Norges Bank102,400$1.59M0.00%
Point72 Asset Management, L.P.97,300$1.51M0.01%
Two Sigma Investments, LP89,863$1.39M0.00%
Millennium Management LLC69,943$1.08M0.00%
Renaissance Technologies LLC53,200$825.0K0.00%
Altium Capital Management LP33,492$519.0K0.14%
Two Sigma Advisers, LP16,500$256.0K0.00%
Algert Global LLC16,146$250.0K0.03%
Jump Financial, LLC16,100$250.0K0.02%
Credit Suisse AG13,624$211.0K0.00%
SG Americas Securities, LLC8,383$130.0K0.00%
Macquarie Group Ltd5,786$90.0K0.00%
Advisor Group Holdings, Inc.4,500$70.0K0.00%
O'Shaughnessy Asset Management, LLC3,261$51.0K0.00%
Point72 Hong Kong Ltd1,357$21.0K0.00%

Sold out (6)

Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of ALGS in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
VR Adviser, LLC408,377$8.32M
Acuta Capital Partners, LLC214,254$4.37M
Jacobs Levy Equity Management, Inc24,889$507.0K
Citadel Advisors LLC16,355$334.0K
Qube Research & Technologies Ltd15,237$311.0K
Hamilton Lane Advisors LLC12,127$247.0K